Key result
Recent-onset DCM is linked to ~58% higher MD-2 plasma levels, driving monocyte-related inflammation.
Why the study?
Plasma levels of MD-2 independently predict mortality in DCM, but whether monocyte activation by MD-2 contributes to immune activation and inflammatory status was untested.
Case-Control (n=50)
Absolute Event Rate: 1250% vs 793.4%
p-value: p=< 0.001
Elevated MD-2 levels in dilated cardiomyopathy contribute to monocyte activation and inflammation, suggesting a potential mechanistic role in disease progression.
May indicate monocyte-driven inflammation in recent-onset DCM; hypothesis-generating for targeted therapies.
Plasma levels of myeloid differentiation factor-2 (MD-2), a co-receptor of toll-like-receptor 4 (TLR4), independently predict mortality in patients with dilated cardiomyopathy (DCM). We tested whether monocyte activation by MD-2 contributes to immune activation and inflammatory status in DCM patients. We found increased MD-2 plasma levels in 25 patients with recent-onset DCM (1250 ± 80.7 ng/ml) compared to 25 age- and gender-matched healthy controls (793.4 ± 52.0 ng/ml; p < 0.001). Monocytes isolated from DCM patients showed a higher expression (141.7 ± 12.4%; p = 0.006 vs. controls) of the MD-2 encoding gene, LY96 and an increased NF-κB-activation. Further, the TLR4-activator lipopolysaccharide (LPS) caused a higher increase in interleukin (IL)-6 in monocytes from DCM patients compared to controls (mean fluorescence intensity: 938.7 ± 151.0 vs. 466.9 ± 51.1; p = 0.005). MD-2 increased IL-6 secretion in a TLR4/NF-κB-dependent manner in monocyte-like THP-1-cells as demonstrated by TLR4-siRNA and NF-κB-inhibition. Since endothelial cells (ECs) are responsible for recruiting monocytes to the site of inflammation, ECs were treated with MD-2 leading to an activation of Akt and increased secretion of monocyte-chemoattractant-protein-1 (MCP-1). Activation of ECs by MD-2 was accompanied by an increased expression of the adhesion molecules CD54, CD106 and CD62E, resulting in an increased monocyte recruitment, which was attenuated by CD54 inhibition. In addition, in murine WT but not LY96-KO bone marrow-derived macrophages LPS increased the amount of CD54 and CD49d/CD29. MD-2 facilitates a pro-inflammatory status of monocytes and EC-mediated monocyte recruitment via TLR4/NF-κB. Elevated MD-2 plasma levels are possibly involved in monocyte-related inflammation-promoting disease progression in DCM. Our results suggest that MD-2 contributes to increasing monocytic inflammatory activity and triggers the recruitment of monocytes to ECs in DCM.
No takes yet. Share an insight, caveat, or question.
Feldtmann et al. (2022) conducted a case-control in Dilated cardiomyopathy (n=50). Recent-onset dilated cardiomyopathy vs. Healthy controls was evaluated on MD-2 plasma levels (p=< 0.001). Recent-onset dilated cardiomyopathy was associated with significantly higher MD-2 plasma levels compared to healthy controls (1250 vs 793.4 ng/ml; p<0.001), driving monocyte-related inflammation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: